Skip to main content
. 2019 Mar 28;10(5):1096–1102. doi: 10.1111/1759-7714.13050

Figure 2.

Figure 2

Kaplan–Meier curves of overall survival (OS) from the beginning of crizotinib resistance. (a) Patients with long progression‐free survival (PFS, ≥ 10.4 months) with crizotinib achieved longer median OS than those with short PFS (median, 28.9 vs. 10.8 months; P = 0.001). (b) A significant difference was observed in OS according to sequential therapy options (median, next‐generation ALK inhibitors 27.6 months vs. crizotinib continuation plus local therapy 13.3 months vs. chemotherapy 9.0 months; P = 0.002). CI, confidence interval. (a) (Inline graphic) PFS ≥ 10.4 months, (Inline graphic) PFS < 10.4 months. (b) (Inline graphic) Next‐generation ALKi, (Inline graphic) Crizotinib continuation, (Inline graphic) Chemotherapy.